HENDERSON, Nev. / Apr 03, 2024 / Business Wire / P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that management is scheduled to present at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 1:30 pm Eastern Time.
A webcast of the presentation will be available on P3’s Investor Relations Website: https://ir.p3hp.org/. A replay will be available on P3’s investor relations webpage for 30 days following the presentation.
About P3 Health Partners (NASDAQ: PIII)
P3 Health Partners Inc. is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 2,700 affiliated primary care providers across the country. Our local teams of health care professionals manage the care of thousands of patients in 18 counties across five states. P3 supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the P3 care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. For more information, visit www.p3hp.org and follow us on LinkedIn and Facebook.com/p3healthpartners.
| Last Trade: | US$0.20 |
| Daily Change: | -0.009 -4.31 |
| Daily Volume: | 876,868 |
| Market Cap: | US$32.570M |
November 27, 2024 November 12, 2024 October 17, 2024 August 21, 2024 August 07, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
